| **MTUS EVIDENCE BASED UPDATES**  | **RULEMAKING COMMENTS****30 DAY COMMENT PERIOD** | **NAME OF PERSON/ AFFILIATION** | **RESPONSE** | **ACTION** |
| --- | --- | --- | --- | --- |
| General Comment | Commenter has reviewed the proposed update and has no comment at this time. | Andrea GuzmanClaims Regulatory DirectorState Compensation Insurance Fund (SCIF)September 3, 2020Written Comment | Noted. | None. |
| General Comment | Commenter supports this update to the Medical Treatment Utilization Schedule, ensuring that treatment for injured workers remains governed by evidence-based guidelines that are the most current available from ACOEM. However, commenter notes that the proposed Antiemetic Guidelines does not appear to differentiate drugs that are appropriate for self-administration as opposed to drugs that are specifically intended to counteract the effects of chemotherapy. Commenter recommends that the Division provide greater clarification for the use of these drugs in the MTUS Drug formulary. | Jackie SeciaCWCI Claims and Medical DirectorCalifornia Workers’ Compensation Institute (CWCI)September 9, 2020Written Comment | Noted and Disagree in part. DWC notes and appreciates commenter’s support of this update to the MTUS. Disagree in part to commenter’s recommendation to provide greater clarification to the use of antiemetics drugs in the MTUS Drug Formulary because it is a recommendation that goes beyond the scope of this rulemaking. | None.  |